Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents

Diabetes Technology and Therapeutics

Volumn 12, Issue 2, 2010, Pages 135-141

  Heise, T ^a   Mathieu, C ^b   Hey Hadavi, J ^c   Strack, T ^c   Lawrence, D ^c  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INCREASED APPETITE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SELF MONITORING; SIDE EFFECT; THORAX DISEASE; WEIGHT GAIN;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 76449087391     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0105     Document Type: Article

References (28)

1. National Diabetes Information Clearinghouse: National Diabetes Statistics, 2007. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Disease. http://diabetes .niddk.nih.gov/dm/pubs/statistics/#y-people (accessed November 5, 2008).
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
3. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49: 1711-1721. (Pubitemid 44025023)
4. Brown JB, Nichols GA, Perry A: The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-1540.
5. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH: Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-2044.
6. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-636.
7. Yki-Jarvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-1136.
8. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
9. Hunt LM, Valenzuela MA, Pugh JA: NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20:292-298.
10. Overmann H, Heinemann L: Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43:137-142.
11. Rave K, Bott S, Heinemann L, Sha S, Becker RHA, Willavize SA, Heise T: Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28:1077-1082.
12. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan SP, Cefalu WT: Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;143: 549-558.
13. Heise T, Mathieu C, Hey-Hadavi J, Strack T, Lawrence DE: Inhaled insulin (Exubera) achieves better A1c levels than insulin glargine in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetic agents [abstract]. Diabetes 2009;58(Suppl 1):2054-PO.
14. Becker RH, Sha S, Frick AD, Fountaine RJ: The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006;29:277-282.
15. Henry RR, Mudaliar SR, Howland WC III, Chu N, Kim D, An B, Reinhardt RR: Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003;26:764-769.
16. Standards of medical care in diabetes. Diabetes Care 2005;28(Suppl 1):S4-S36.
17. McKeage K, Goa KL: Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001;61:1599-1624.
18. Del Prato S, Blonde L, Martinez L, Goeke B, Woo V, Millward A, Gomis R, Canovatchel B, Strack T, Lawrence D, Freemantle N: The effect of the availability of inhaled insulin on glycaemic control in patients with type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial. Diabet Med 2008;25:662-670.
19. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M: An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006;29:1282-1287. (Pubitemid 44125923)
20. Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M: Longterm tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. Int J Clin Pract 2007;61:1614-1625.
21. Biermann E, Dietrich W, Rihl J, Standl E: Are there time and cost savings by using telemanagement for patients on intensified insulin therapy? A randomised, controlled trial. Comput Methods Programs Biomed 2002;69:137-146.
22. Kalfhaus J, Berger M: Insulin treatment with preprandial injections of regular insulin in middle-aged type 2 diabetic patients. A two years observational study. Diabetes Metab 2000;26:197-201.
23. Hollander PA, Krasner A, Klioze S, Schwartz P, Duggan W: Body weight changes associated with insulin therapy: a retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled Phase III trials. Diabetes Care 2007;30:2508-2510.
24. Quattrin T: Inhaled insulin: a novel and non-invasive way for insulin administration? Curr Drug Saf 2006;1:151-158.
25. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-2362.
26. Norwood P, Dumas R, Cefalu W, Yale JF, England R, Riese R, Teeter J: Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (Exubera). J Clin Endocrinol Metab 2007;92:2211-2214.
27. Rosenstock J, Cefalu W, Hollander PA, Belanger A, Eliaschwitz FG, Gross JL, Klioze S, St Aubin L, Foyt H, Ogawa M, Duggan W: Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care 2008;31:1723-1728.
28. Havas S: The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom. Arch Intern Med 2009;169:150-154.